Pfizer Inc. (NYSE:PFE) Shares Sold by Meridian Wealth Partners LLC

Meridian Wealth Partners LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,883 shares of the biopharmaceutical company’s stock after selling 1,706 shares during the period. Meridian Wealth Partners LLC’s holdings in Pfizer were worth $256,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Investment Advisory Services Inc. TX ADV grew its holdings in shares of Pfizer by 1.6% in the 3rd quarter. Investment Advisory Services Inc. TX ADV now owns 20,097 shares of the biopharmaceutical company’s stock worth $667,000 after acquiring an additional 325 shares during the last quarter. Trifecta Capital Advisors LLC increased its stake in Pfizer by 3.7% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 325 shares in the last quarter. Confluence Wealth Services Inc. raised its holdings in Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after buying an additional 342 shares during the period. Carr Financial Group Corp lifted its stake in Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after buying an additional 355 shares in the last quarter. Finally, Caldwell Sutter Capital Inc. boosted its holdings in shares of Pfizer by 0.5% in the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after buying an additional 364 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.6 %

NYSE PFE traded up $0.14 during trading on Friday, reaching $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The business has a 50-day moving average price of $26.96 and a 200-day moving average price of $28.39. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The stock has a market capitalization of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.